 Abdelrahman Fouda
Concepts (205)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retina | 9 | 2026 | 76 | 3.500 |
Why?
| | Reperfusion Injury | 8 | 2026 | 82 | 3.360 |
Why?
| | Retinal Diseases | 6 | 2025 | 59 | 3.160 |
Why?
| | Arginase | 10 | 2023 | 40 | 2.610 |
Why?
| | Histone Deacetylases | 3 | 2026 | 59 | 1.950 |
Why?
| | Neuroprotective Agents | 5 | 2021 | 101 | 1.890 |
Why?
| | Stroke | 10 | 2022 | 520 | 1.730 |
Why?
| | Retinal Neovascularization | 3 | 2025 | 7 | 1.560 |
Why?
| | Receptor, Angiotensin, Type 2 | 4 | 2022 | 23 | 1.500 |
Why?
| | Phagocytosis | 3 | 2026 | 59 | 1.360 |
Why?
| | Macrophages | 7 | 2026 | 380 | 1.330 |
Why?
| | Mice, Inbred C57BL | 11 | 2026 | 1925 | 1.260 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 4 | 2019 | 44 | 1.200 |
Why?
| | Mice, Knockout | 9 | 2026 | 910 | 1.200 |
Why?
| | Renin-Angiotensin System | 3 | 2019 | 58 | 1.190 |
Why?
| | Animals | 32 | 2026 | 13526 | 1.090 |
Why?
| | Thiophenes | 5 | 2022 | 45 | 1.000 |
Why?
| | Diabetic Retinopathy | 3 | 2025 | 50 | 0.980 |
Why?
| | Brain | 7 | 2021 | 1350 | 0.960 |
Why?
| | Sulfonamides | 5 | 2022 | 139 | 0.930 |
Why?
| | Eye | 1 | 2025 | 29 | 0.930 |
Why?
| | Eye Diseases | 1 | 2025 | 36 | 0.920 |
Why?
| | Ischemia | 3 | 2024 | 158 | 0.920 |
Why?
| | Infarction, Middle Cerebral Artery | 6 | 2022 | 41 | 0.880 |
Why?
| | Aqueous Humor | 1 | 2024 | 10 | 0.860 |
Why?
| | Retinal Artery Occlusion | 1 | 2024 | 11 | 0.860 |
Why?
| | Drug Delivery Systems | 2 | 2025 | 148 | 0.850 |
Why?
| | Nanoparticles | 1 | 2025 | 133 | 0.840 |
Why?
| | Mice | 14 | 2026 | 5982 | 0.790 |
Why?
| | Retinopathy of Prematurity | 1 | 2022 | 16 | 0.750 |
Why?
| | Proteomics | 1 | 2024 | 336 | 0.710 |
Why?
| | Endothelial Cells | 7 | 2025 | 289 | 0.700 |
Why?
| | Minocycline | 2 | 2017 | 15 | 0.650 |
Why?
| | Luminescent Agents | 1 | 2020 | 1 | 0.640 |
Why?
| | Brain Injuries | 1 | 2021 | 160 | 0.640 |
Why?
| | Muramidase | 1 | 2020 | 15 | 0.640 |
Why?
| | Integrases | 1 | 2020 | 44 | 0.640 |
Why?
| | Luminescent Proteins | 1 | 2020 | 48 | 0.630 |
Why?
| | Retinal Vessels | 1 | 2020 | 20 | 0.630 |
Why?
| | Cadherins | 1 | 2020 | 62 | 0.620 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 73 | 0.610 |
Why?
| | Endothelins | 1 | 2019 | 16 | 0.600 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2016 | 8 | 0.590 |
Why?
| | Antigens, CD | 1 | 2020 | 217 | 0.580 |
Why?
| | Inflammation | 3 | 2021 | 652 | 0.570 |
Why?
| | Rats, Wistar | 8 | 2022 | 192 | 0.570 |
Why?
| | Cerebrovascular Circulation | 1 | 2019 | 132 | 0.550 |
Why?
| | Disease Models, Animal | 12 | 2023 | 1517 | 0.540 |
Why?
| | Cognition Disorders | 1 | 2019 | 199 | 0.540 |
Why?
| | Interleukin-10 | 1 | 2017 | 81 | 0.500 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2016 | 30 | 0.500 |
Why?
| | Cerebral Hemorrhage | 1 | 2017 | 102 | 0.490 |
Why?
| | Cognition | 1 | 2019 | 346 | 0.480 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2016 | 7 | 0.480 |
Why?
| | Apoptosis | 4 | 2026 | 1139 | 0.460 |
Why?
| | Endothelium, Vascular | 5 | 2022 | 262 | 0.450 |
Why?
| | Microglia | 4 | 2025 | 113 | 0.430 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2022 | 138 | 0.420 |
Why?
| | Myeloid Cells | 2 | 2024 | 45 | 0.410 |
Why?
| | Optic Nerve Injuries | 2 | 2023 | 7 | 0.390 |
Why?
| | Brain Ischemia | 4 | 2021 | 162 | 0.380 |
Why?
| | Neovascularization, Physiologic | 3 | 2022 | 86 | 0.380 |
Why?
| | Tetrazoles | 4 | 2018 | 41 | 0.370 |
Why?
| | Benzimidazoles | 4 | 2018 | 50 | 0.370 |
Why?
| | Rats | 7 | 2022 | 3162 | 0.360 |
Why?
| | Polyethylene Glycols | 2 | 2022 | 95 | 0.350 |
Why?
| | Recovery of Function | 6 | 2019 | 203 | 0.330 |
Why?
| | Male | 15 | 2024 | 27435 | 0.330 |
Why?
| | Humans | 17 | 2025 | 53230 | 0.320 |
Why?
| | Blood-Brain Barrier | 2 | 2021 | 51 | 0.320 |
Why?
| | Oxygen | 3 | 2025 | 338 | 0.310 |
Why?
| | Neovascularization, Pathologic | 3 | 2022 | 158 | 0.300 |
Why?
| | Neurons | 2 | 2021 | 394 | 0.270 |
Why?
| | Diabetes Mellitus | 3 | 2016 | 321 | 0.260 |
Why?
| | Administration, Ophthalmic | 1 | 2025 | 4 | 0.240 |
Why?
| | Ornithine | 2 | 2023 | 17 | 0.240 |
Why?
| | Thromboembolism | 2 | 2018 | 48 | 0.240 |
Why?
| | Nanotechnology | 1 | 2025 | 31 | 0.240 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2024 | 10 | 0.220 |
Why?
| | Vitreous Body | 1 | 2024 | 19 | 0.220 |
Why?
| | Paracentesis | 1 | 2024 | 13 | 0.220 |
Why?
| | Eye Proteins | 1 | 2024 | 17 | 0.210 |
Why?
| | Biphenyl Compounds | 4 | 2018 | 31 | 0.210 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2021 | 21 | 0.210 |
Why?
| | Ornithine Decarboxylase | 1 | 2023 | 12 | 0.210 |
Why?
| | Vitrectomy | 1 | 2024 | 61 | 0.200 |
Why?
| | Imidazoles | 2 | 2022 | 114 | 0.200 |
Why?
| | Retinal Ganglion Cells | 2 | 2020 | 15 | 0.200 |
Why?
| | Mass Spectrometry | 1 | 2024 | 294 | 0.190 |
Why?
| | Motor Activity | 3 | 2019 | 227 | 0.190 |
Why?
| | Signal Transduction | 6 | 2022 | 1748 | 0.190 |
Why?
| | Mice, Transgenic | 2 | 2021 | 561 | 0.180 |
Why?
| | Blood-Retinal Barrier | 1 | 2021 | 6 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 38 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 392 | 0.180 |
Why?
| | Copper | 1 | 2022 | 47 | 0.180 |
Why?
| | Mitochondria | 2 | 2025 | 446 | 0.170 |
Why?
| | Optic Neuritis | 1 | 2021 | 21 | 0.170 |
Why?
| | Behavior, Animal | 2 | 2019 | 187 | 0.170 |
Why?
| | Cytokines | 1 | 2023 | 627 | 0.160 |
Why?
| | Recombinant Proteins | 1 | 2021 | 489 | 0.160 |
Why?
| | Genes, Reporter | 1 | 2020 | 87 | 0.160 |
Why?
| | Nitric Oxide | 2 | 2018 | 233 | 0.160 |
Why?
| | Cell Survival | 1 | 2021 | 600 | 0.160 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 421 | 0.150 |
Why?
| | Recombination, Genetic | 1 | 2020 | 95 | 0.150 |
Why?
| | Retinal Degeneration | 1 | 2019 | 10 | 0.150 |
Why?
| | Receptors, Endothelin | 1 | 2019 | 6 | 0.150 |
Why?
| | Receptors, Angiotensin | 1 | 2019 | 11 | 0.150 |
Why?
| | Animals, Newborn | 1 | 2020 | 357 | 0.150 |
Why?
| | Female | 6 | 2024 | 28782 | 0.150 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2018 | 64 | 0.140 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 176 | 0.140 |
Why?
| | Nitric Oxide Synthase | 1 | 2018 | 64 | 0.140 |
Why?
| | Forecasting | 1 | 2019 | 152 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2019 | 77 | 0.140 |
Why?
| | Gene Deletion | 1 | 2019 | 279 | 0.140 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2018 | 83 | 0.140 |
Why?
| | Cattle | 3 | 2025 | 207 | 0.130 |
Why?
| | Vascular Stiffness | 1 | 2017 | 24 | 0.130 |
Why?
| | Administration, Intravenous | 1 | 2017 | 73 | 0.130 |
Why?
| | Tissue Plasminogen Activator | 1 | 2018 | 108 | 0.130 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 132 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2025 | 1569 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2017 | 75 | 0.130 |
Why?
| | Biomedical Research | 1 | 2020 | 267 | 0.130 |
Why?
| | Acute Disease | 1 | 2017 | 393 | 0.120 |
Why?
| | Injections, Intraventricular | 1 | 2016 | 12 | 0.120 |
Why?
| | Angiotensins | 1 | 2016 | 12 | 0.120 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2016 | 56 | 0.120 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 214 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2019 | 338 | 0.110 |
Why?
| | Infant, Newborn | 1 | 2022 | 2913 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 138 | 0.110 |
Why?
| | Neuronal Plasticity | 1 | 2014 | 44 | 0.110 |
Why?
| | Thioredoxins | 1 | 2014 | 26 | 0.100 |
Why?
| | Cerebral Cortex | 1 | 2014 | 194 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2014 | 315 | 0.090 |
Why?
| | Optic Nerve | 2 | 2023 | 46 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 591 | 0.080 |
Why?
| | Hypertension | 1 | 2016 | 554 | 0.080 |
Why?
| | Blood Pressure | 3 | 2018 | 518 | 0.080 |
Why?
| | Aged | 1 | 2024 | 10429 | 0.080 |
Why?
| | Cell Movement | 2 | 2025 | 279 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2017 | 5595 | 0.080 |
Why?
| | Obesity | 1 | 2017 | 1204 | 0.070 |
Why?
| | Middle Aged | 1 | 2024 | 13419 | 0.070 |
Why?
| | Time Factors | 3 | 2019 | 2991 | 0.060 |
Why?
| | Random Allocation | 2 | 2018 | 284 | 0.060 |
Why?
| | Phenylenediamines | 1 | 2025 | 7 | 0.060 |
Why?
| | Acrylamides | 1 | 2025 | 12 | 0.060 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2025 | 60 | 0.060 |
Why?
| | Glycolysis | 1 | 2025 | 76 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2015 | 189 | 0.050 |
Why?
| | Nerve Crush | 1 | 2023 | 2 | 0.050 |
Why?
| | Glutamates | 1 | 2023 | 21 | 0.050 |
Why?
| | Glucose | 1 | 2025 | 361 | 0.050 |
Why?
| | Cysteine | 1 | 2022 | 50 | 0.040 |
Why?
| | Mitochondrial Dynamics | 1 | 2021 | 22 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 102 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2022 | 235 | 0.040 |
Why?
| | Oxidative Stress | 2 | 2017 | 819 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 333 | 0.040 |
Why?
| | Neuroglia | 1 | 2019 | 39 | 0.040 |
Why?
| | Cell Line | 1 | 2022 | 1016 | 0.040 |
Why?
| | Microvessels | 1 | 2019 | 36 | 0.040 |
Why?
| | Sensory Gating | 1 | 2018 | 1 | 0.040 |
Why?
| | Rats, Inbred SHR | 1 | 2018 | 42 | 0.040 |
Why?
| | PPAR gamma | 1 | 2019 | 74 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2018 | 82 | 0.030 |
Why?
| | Locomotion | 1 | 2018 | 79 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2018 | 65 | 0.030 |
Why?
| | Dietary Sucrose | 1 | 2017 | 14 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 456 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2018 | 209 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 130 | 0.030 |
Why?
| | Vasodilation | 1 | 2017 | 100 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 198 | 0.030 |
Why?
| | Hippocampus | 1 | 2018 | 195 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2018 | 729 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 726 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 747 | 0.030 |
Why?
| | Arginine | 1 | 2017 | 178 | 0.030 |
Why?
| | Hydro-Lyases | 1 | 2015 | 2 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2017 | 371 | 0.030 |
Why?
| | Brain Infarction | 1 | 2015 | 13 | 0.030 |
Why?
| | Cerebrovascular Trauma | 1 | 2015 | 11 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 243 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2016 | 124 | 0.030 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 47 | 0.030 |
Why?
| | Insulin | 1 | 2017 | 493 | 0.030 |
Why?
| | Blood Glucose | 1 | 2017 | 490 | 0.030 |
Why?
| | Middle Cerebral Artery | 1 | 2015 | 34 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2015 | 126 | 0.030 |
Why?
| | Cell Communication | 1 | 2015 | 73 | 0.030 |
Why?
| | Phenotype | 1 | 2017 | 803 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 533 | 0.030 |
Why?
| | Muscle Strength | 1 | 2015 | 132 | 0.030 |
Why?
| | Comorbidity | 1 | 2016 | 638 | 0.030 |
Why?
| | Stilbenes | 1 | 2014 | 58 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2015 | 218 | 0.030 |
Why?
| | Pyridines | 1 | 2015 | 135 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2014 | 227 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 466 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 1031 | 0.020 |
Why?
|
|
Fouda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|